Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
View Top Employees from Arbutus Biopharma CorporationWebsite | http://www.arbutusbio.com |
Ticker | ABUS |
Revenue | $5 million |
Funding | $116 million |
Employees | 113 (113 on RocketReach) |
Founded | 1992 |
Address | 701 Veterans Circle, Warminster, Pennsylvania 18974, US |
Phone | (267) 469-0914 |
Fax | (267) 282-0411 |
Technologies |
JavaScript,
HTML,
PHP
+38 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biopharma, Business Services, Biotechnology, Health Care, Science and Engineering, Genetics, Medical, Pharmaceutical |
Web Rank | 3 Million |
Keywords | Arbutus Biopharma, Ab-729, Tekmira Pharmaceuticals, Arbutus, Dna Sequence To Induce Sirna Production |
Competitors | Alzheon, Inc. | Preserving Future Memories, Chimerix, Inc., DTANK+, Quark Pharmaceuticals Inc, ReViral |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies, NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular Arbutus Biopharma Corporation employee's phone or email?
The Arbutus Biopharma Corporation annual revenue was $5 million in 2024.
Lisa Caperelli is the Vice President of Investor Relations of Arbutus Biopharma Corporation.
113 people are employed at Arbutus Biopharma Corporation.
Arbutus Biopharma Corporation is based in Warminster, Pennsylvania.
The NAICS codes for Arbutus Biopharma Corporation are [541, 325, 3254, 54, 32, 5417, 541714, 54171].
The SIC codes for Arbutus Biopharma Corporation are [87, 873].